Shore, N. D., Chakrabarti, J., Narayanan, S., Lin, S., Schweizer, M. T. (2025). Mevrometostat in combination with enzalutamide for androgen receptor pathway inhibitor (ARPI)-naïve patients with metastatic castration-resistant prostate cancer (mCRPC): The phase 3, randomized MEVPRO-2 study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps5116